Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Non Small Cell Lung Cancer.

Trial Profile

Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Non Small Cell Lung Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2011

At a glance

  • Drugs Glufosfamide (Primary)
  • Indications Lung cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jul 2008 Planned patient is now 32 as reported by ClinicalTrials.gov.
    • 18 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top